Biosplice Therapeutics
(Redirected from Samumed)
| Company type | Privately held company |
|---|---|
| Industry | Regenerative medicine |
| Founded | 2008 in San Diego, USA |
| Founder | Osman Kibar |
| Fate | renamed from Samumed |
| Headquarters | San Diego, USA |
| Website | www |
Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.[1] It was founded in 2008 by Osman Kibar.[2]
Samumed's products in development target novel components of the Wnt signaling pathway.[3][4][5] The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced.[4][6]
References
[edit]- ^ "Small-molecule therapeutics using Biosplice Therapeutics". Business Outreach. 2023-08-16. Retrieved 2024-07-06.
- ^ "Forbes Profile: Osman Kibar", "Forbes"
- ^ Herper, Matthew."Cure Baldness? Heal Arthritis? Erase Wrinkles? An Unknown Billionaire's Quest To Reverse Aging", "Forbes", May 10, 2016
- ^ a b Ramsey, Lydia. "A $12 billion startup you've probably never heard wants to cure baldness and smooth out your wrinkles", "Business Insider", April 2, 2017
- ^ Lee, Yoolim. "Eternal Youth Is the Next Big Bet for Singapore Venture Capitalist", "Bloomberg", February 9, 2017
- ^ Jackson, Mandy. "ACR Notebook: Lilly's Baricitinib Differentiates On Pain, Ironwood's Duzallo Progress, Corbus Nears Phase III", "Informa Scrip", November 8, 2017"
 | This corporation or company article is a stub. You can help Wikipedia by expanding it. |